Drug-induced acute liver failure

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 575-586

  Lee, William M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Coagulopathy; Encephalopathy; Hepatocyte injury; Liver transplantation

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; CARBAMAZEPINE; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; DICLOFENAC; DISULFIRAM; ETODOLAC; GEMTUZUMAB; HERBACEOUS AGENT; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; METHYLDOPA; NITROFURANTOIN; PARACETAMOL; PHENYTOIN; PLACEBO; PROPYLTHIOURACIL; RIFAMPICIN PLUS TRIMETHOPRIM; TELITHROMYCIN; TERBINAFINE; UNINDEXED DRUG; VALPROIC ACID;

ACUTE LIVER FAILURE; AUTOIMMUNE HEPATITIS; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HOSPITALIZATION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LIVER NECROSIS; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SHORT TERM SURVIVAL; TOXIC HEPATITIS; UNITED STATES;

COAGULOPATHY; ENCEPHALOPATHY; HEPATOCYTE INJURY; LIVER TRANSPLANTATION;

DRUG-INDUCED LIVER INJURY; HUMANS; LIVER FAILURE, ACUTE;

EID: 84884954702     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.001     Document Type: Review

References (34)

1. Ostapowicz G.A., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:945-954.
2. Schiødt F.V., Atillasoy E., Shakil O., et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999, 5:29-34.
3. Bernal W., Auzinger G., Dhawan A., et al. Acute liver failure. Lancet 2010, 376:190-201.
4. Zimmerman H.J., Maddrey W.C. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995, 22:767-773.
5. Wootton F.T., Lee W.M. Acetaminophen hepatotoxicity in the alcoholic. South Med J 1990, 83:1047-1049.
6. Schiødt F.V., Rochling F.J., Casey D.L., et al. Acetaminophen toxicity in an urban county hospital. NEngl J Med 1997, 337:1112-1117.
7. Khandelwal N., James L.P., Sanders C., Acute Liver Failure Study Group, et al. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011, 53:567-576.
8. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005, 4:489-499.
9. Tujios S., Fontana R.J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011, 8:202-211.
10. Lee W.M., Senior J.R. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005, 33:155-164.
11. Daly A.K., Donaldson P.T., Bhatnagar P., et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-819.
12. Urban T.J. Whole-genome sequencing in pharmacogenetics. Pharmacogenomics 2013, 14:345-348.
13. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934.
14. Reuben A., Koch D.G., Lee W.M. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52:2065-2076.
15. Brinker A.D., Wassel R.T., Lyndly J., et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009, 49:250-257.
16. Soreth J., Cox E., Kweder J., et al. Ketek: the FDA perspective. NEngl J Med 2007, 356:1675-1676.
17. Jones D.P., Lemasters J.J., Han D., et al. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol Interv 2010, 10:98-111.
18. Stravitz R.T., Kramer A.H., Davern T., Acute Liver Failure Study Group, et al. Intensive care of patients with acute liver failure: recommendations of the Acute Liver Failure Study Group. Crit Care Med 2007, 35:2498-2508.
19. Lee W.M., Stravitz R.T., Larson A.M. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology 2012, 55:965-967.
20. Davern T.J., Chalasani N., Fontana R., et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011, 141:1665-1672.
21. Lee W.M., Hynan L.S., Rossaro L., et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137:856-864.
22. Singh S., Hynan L.S., Lee W.M., Acute Liver Failure Study Group Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 2013, 58(5):1397-1402.
23. Ichai P., Duclos-Vallée J., Guettier C., et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007, 13:996-1003.
24. Jalan R., Wright G., Davies N.A., et al. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 2007, 69:1064-1069.
25. Lee W.M., Jalan R.V. Treatment of hyperammonemia in liver failure: a tale of two enzymes. Gastroenterology 2009, 136:2048-2051.
26. Larson A.M., Fontana R.J., Davern T.J., Acute Liver Failure Study Group, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42:1367-1372.
27. Russo M., Galanko J.A., Shrestha R., et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004, 10:1018-1023.
28. Cholongitas E., Theocharidou E., Vasianopoulou P., et al. Comparison of the sequential organ failure assessment score with the king's college hospital criteria and the model for end-stage liver disease score for the prognosis of acetaminophen-induced acute liver failure. Liver Transpl 2012, 18:405-412.
29. Taylor R.M., Davern T.J., Munoz S., Acute Liver Failure Study Group, et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology 2006, 44:1589-1597.
30. Rutherford A., King L.Y., Hynan L.S., Acute Liver Failure Study Group, et al. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology 2012, 143:1237-1243.
31. Bechmann L.P., Jochum C., Kocabayoglu P., et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. JHepatol 2010, 53:639-647.
32. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006, 15:241-243.
33. Strnad P., Zhou Q., Hanada S., Acute Liver Failure Study Group, et al. Ethnic-specific keratin variants predispose to an adverse outcome in acute liver failure. Gastroenterology 2010, 139:828-835.
34. Court M.H., Freytsis M., Wang X., et al. The UDP-Glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A Exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. JPharmacol Exp Ther 2013, 345:297-307.